A collection of features and news articles published in ASH Clinical News related to bleeding disorders.
Congress Passes Bipartisan Sickle Cell Bill
The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation...
FDA Approves New Hemophilia A Treatment
The U.S. Food and Drug Administration (FDA) approved turoctocog alfa pegol, formerly known as N8-GP, for the treatment of children and adults with hemophilia...
Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP
Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...
Roche Will Donate Hemophilia A Drug to Developing Countries
Roche will donate its new hemophilia A drug emicizumab-kxwh to the World Hemophilia Federation (WHF) Humanitarian Aid Program. Roche joins other companies – including...
New Drug Approvals in Nonmalignant Hematology
In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...
China First to Approve Oral Drug to Stimulate Erythropoiesis
China’s National Medical Products Administration approved the oral anemia drug roxadustat, well before regulators in the U.S. or Europe have issued decisions. The hypoxia-inducible...
FDA Approves New Hemophilia A Drug
The FDA has approved emicizumab-kxwh as prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A...
Emicizumab Prophylaxis Reduces Bleeding Events in Hemophilia A Without Inhibitors
Treatment with emicizumab was associated with lower bleeding rates, compared with no prophylaxis, in patients with hemophilia A without inhibitors, according to findings from...
No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...
Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...
FDA Approves New Treatment for Hemophilia
The U.S. Food and Drug Administration (FDA) approved BAY94-9027, or antihemophilic factor (recombinant), PEGylated-aucl, for the prophylactic treatment of adults and adolescents (≥12 years)...
